Isomorphic Labs has secured $5 billion in fresh capital, marking its second billion-dollar funding round within a six-month period. Greenoaks and Sequoia Capital co-led the investment, joined by Andreessen Horowitz and existing backers including Alphabet. The firm will direct these funds toward advancing its IsoDDE platform and moving its drug pipeline closer to clinical trials. This internal design engine claims to improve predictions of drug binding and docking sites beyond the capabilities of AlphaFold 3. The company currently collaborates with Novartis, Eli Lilly, and Johnson & Johnson but holds no approved drugs to date. Demis Hassabis leads the organisation, having stepped down from day-to-day management of Google Deepmind in August 2026 to serve as Alphabet’s Chief Scientist. Hassabis previously won the 2024 Nobel Prize in Chemistry for work on AlphaFold alongside John Jumper.
The funding confirms significant investor confidence in the commercial potential of computational biology despite the absence of approved products. It also highlights a major restructuring of Google Deepmind, where the original AlphaFold team disbanded in July 2026. Many researchers transferred to Isomorphic Labs or other projects, while nearly a quarter left Deepmind entirely. Deepmind continues to operate independently, shipping AlphaGenome 2 in early November 2026 to predict DNA variant effects.
- Investors include Greenoaks, Sequoia Capital, Andreessen Horowitz, and Alphabet.
- Funds target IsoDDE development and clinical trial advancement.
- Deepmind AlphaFold team disbanded in July 2026 with many staff moving to Isomorphic Labs.




